KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Inovio Pharmaceuticals (INO) FCF Margin (2016 - 2025)

Inovio Pharmaceuticals' FCF Margin history spans 16 years, with the latest figure at 41218.49% for Q1 2025.

  • For Q1 2025, FCF Margin changed N/A year-over-year to 41218.49%; the TTM value through Sep 2025 reached 48855.17%, up 580027.0%, while the annual FY2024 figure was 48019.06%, 3303289.0% down from the prior year.
  • FCF Margin for Q1 2025 was 41218.49% at Inovio Pharmaceuticals, down from 16807.62% in the prior quarter.
  • Across five years, FCF Margin topped out at 737.94% in Q3 2022 and bottomed at 41218.49% in Q1 2025.
  • The 5-year median for FCF Margin is 16807.62% (2024), against an average of 19739.04%.
  • The largest YoY upside for FCF Margin was 2214783bps in 2022 against a maximum downside of -2412171bps in 2022.
  • A 5-year view of FCF Margin shows it stood at 4470.02% in 2021, then plummeted by -540bps to 28591.73% in 2022, then increased by 10bps to 25597.2% in 2023, then skyrocketed by 34bps to 16807.62% in 2024, then plummeted by -145bps to 41218.49% in 2025.
  • Per Business Quant, the three most recent readings for INO's FCF Margin are 41218.49% (Q1 2025), 16807.62% (Q4 2024), and 27960.71% (Q2 2024).